Drug intelligence / Profile preview

Qianlieping

Development stage: Unknown
Lead developer: Xi'an Qianhe Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Qianlieping is a proprietary Traditional Chinese Medicine (TCM) herbal formulation developed by Xi'an Qianhe Pharmaceutical for the treatment of chronic prostatitis. Administered orally as a capsule, it is specifically indicated for cases presenting with damp-heat and blood stasis syndrome according to TCM diagnostic principles. The formulation is derived from the traditional Danshen Huoxue Tang (Salvia Blood-Activating Decoction) and has a history of human use spanning over 30 years. Its therapeutic actions focus on clearing heat, detoxification, resolving blood stasis, and pain relief. The drug is included in China's National Medical Insurance Category B list and has been granted multiple invention patents.

Brand names: Qianlieping
Other names: Qianlieping capsules前列平胶囊

Beyond the preview

Go deeper on Qianlieping.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qianlieping.

Explore the full profile